Pluvicto

Lutetium (177Lu) vipivotide tetraxetan (INN, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen -positive metastatic castration-resistant prostate cancer. Lutetium vipivotide tetraxetan is a targeted radioligand therapy.

Recent news mentioning Pluvicto

• 2026-07-31 — FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

Appears alongside

• FDA
• PSMA

Browse the full archive →